Today’s episode of The Oncology Journal Club is the second of our ESMO Special Episodes featuring Lung Cancer, Phase 1 Trials and GU Cancers…
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 14 in our series The Oncology Journal Club, the second of our ESMO Special Episodes.
Today’s ESMO Episode features Ben Solomon discussing Lung Cancer with Craig Underhill and our favourite new guest interviewer, Vogl New York! Even though it meant missing the beginning of the footy finals, this interview made Ben’s day.
Craig and Hans chat to Maria Bourlon on the GU highlights, covering a range of papers including one Maria co-authored.
Hans also has a fascinating discussion with Phillippe Aftimos on Phase 1 and Basket trials so this is another great episode packed with expert analysis and thought provoking discussions.
Next week we have our final ESMO Special Episode featuring Amelia McCartney, Eva Segelov and our friend Steve Vogl chatting all things breast cancer so watch out for this one.
With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
Today’s episode is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Solomon, B, et al. Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Tsuboi, M, et al. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Hong, D, et al. Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283. Access online here.
Phase 1 and Basket Trials:
- John, T., et al. Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269. Access online here.
- Rousseau, B., et al.High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours. Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc27. Access online here.
- Lwin, Z., et al. LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Choueiri, T., et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Powles, T., et al. A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. Access online here.
- Powles, T., et al. Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. Access online here.
- Alva, A., et al. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- de Bono, J., et al. Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology (2020) 31 (suppl_4): S507-S549. 10.1016/annonc/annonc275. Access online here.
- de Bono, J., et al. IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
Professor Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
Professor Ben Solomon is a medical oncologist in the Lung Service and the Head & Neck service at the Peter MacCallam Cancer Centre in Melbourne, Victoria, Australia. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He has an interest in translational lung cancer research and completed a PhD investigating the mechanisms by which EGFR inhibition enhance the effects of radiation, and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors.
Professor Solomon practices as a medical oncologist with a research focus on clinical and translational research in lung cancer and head and neck cancer. His clinical trial work focuses on the identification of novel therapies for lung cancer. The Molecular Therapeutics and Biomarkers Laboratory focuses on pre-clinical studies of novel therapies for cancer and, more specifically, identification of prognostic and predictive biomarkers in lung and head and neck cancers.
Philippe Aftimos, MD is a medical oncologist and the Clinical Trials Development Leader at the Clinical Trials Conduct Unit of Institut Jules Bordet, a comprehensive cancer center in Brussels.
He works in the fields of breast cancer, new drug development and precision medicine. At Institut Jules Bordet, he heads the new drug development program at the Clinical Trials Conduct Unit. He has participated in the development of novel monoclonal antibodies and antibody-drug conjugates for the treatment of breast cancer as well as in the development of novel endocrine therapies. He currently leads multiple projects with agents targeting epigenetics. As a clinical research physician, he is a member of the think tank of the Oncodistinct network and is Vice-Chair of the Scientific Executive Committee of the International Breast Cancer Study Group.
Professor Maria Bourlon is a Mexican Medical Oncologist focused on Genitourinary Cancers and Global Oncology. Maria is Head of the Urologic Oncology Clinic at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
In 2014 Maria took a Research Fellowship at the University of Colorado Genitourinary Cancers Program and in 2019 was a ASCO JCO-Global Oncology Fellow Awardee.
Steven Vogl is a medical oncologist in private practice in the Bronx, New York. He pays attention at meetings and occasionally asks a question.
Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Ben Solomon, Phillippe Aftimos, Maria Bourlon, Steven Vogl our Special Guest Interviewer and Graham Knowles.